NIKKEI 225
38,649.15 -454.07 (-1.16%) HANG SENG
18,580.59 -288.12 (-1.53%) CRUDE OIL
76.82 -0.05 (-0.07%) GOLD FUTURES
2,330.40 -6.80 (-0.29%) DOW
39,065.26 -605.78 (-1.53%) Bitcoin GBP
53,463.19 -1,217.23 (-2.23%)
GH Dec 2025 12.500 put
| Previous close | 3.2000 |
| Open | 3.2000 |
| Bid | 1.6000 |
| Ask | 3.1000 |
| Strike | 12.50 |
| Expiry date | 2025-12-19 |
| Day's range | 3.2000 - 3.2000 |
| Contract range | N/A |
| Volume | |
| Open interest | 12 |
Business WireFDA Advisory Committee Panel Strongly Recommends Approval of Shield™ Blood Test for Colorectal Cancer Screening as a Primary Non-Invasive Screening Option
PALO ALTO, Calif., May 23, 2024--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the Molecular and Clinical Genetics Panel of the U.S. Food and Drug Administration (FDA)’s Medical Devices Advisory Committee has strongly recommended FDA approval of the company’s Shield™ blood test for colorectal cancer (CRC) screening in adults age 45 and older who are at average risk for the disease.
Business WireGuardant Health Stock Trading Temporarily Halted; FDA Panel to Assess Premarket Approval Application for Shield Blood Test for Colorectal Cancer Screening
PALO ALTO, Calif., May 23, 2024--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that Nasdaq has temporarily halted trading of the company's stock.
- Business Wire
Guardant Health to Participate in Upcoming Investor Conferences
PALO ALTO, Calif., May 22, 2024--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the following investor conferences.
